Skip to main content
. Author manuscript; available in PMC: 2010 Mar 15.
Published in final edited form as: N Engl J Med. 2010 Jan 20;362(5):427–439. doi: 10.1056/NEJMoa0904849

Figure 2. End Points with Respect to Transmission of HIV-1, According to the Study Group, in the Modified Intention-to-Treat and the Intention-to-Treat Populations.

Figure 2

The 132 seroconversions to HIV-1 excluded 19 in partners who, during confirmatory testing, were found to be seronegative for HIV-1 (i.e., negative for HIV-1 antibodies) but who were infected with HIV-1 (i.e., positive for HIV-1 RNA) at study enrollment and were infected therefore with HIV-1 before their HIV-1–infected partner received acyclovir or placebo. Determination of linkage for transmission pairs was based on viral sequencing in the partner who was originally infected with HIV-1 and that person's partner who underwent seroconversion to HIV-1; linkage data were reviewed by an expert adjudication committee. The modified intention-to-treat analysis excluded HIV-1 transmissions among male partners who underwent seroconversion when their HIV-1–infected female partners were pregnant and not taking the study drug as specified by the protocol (two in the acyclovir group and four in the placebo group).